Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein

Myelin oligodendrocyte glycoprotein (MOG) is an antigen of the myelin sheath, which may trigger immune cell responses and the production of auto‐antibodies in multiple sclerosis (MS). In this study, we used MOG35‐55‐induced experimental autoimmune encephalomyelitis (EAE), a model of human MS, to assess the production of catalytically active immunoglobulin G (IgG) antibodies or abzymes which have been shown to be present in sera of patients with several autoimmune diseases. Here, we show that IgGs from the sera of control C57BL/6 mice are catalytically inactive. During development of EAE, a specific reorganization of the immune system of mice occurred leading to a condition which was associated with the generation of catalytically active IgGs hydrolysing DNA, myelin basic protein (MBP) and MOG which was associated with increased proteinuria, changes in differentiation of mice bone marrow hematopoietic stem cells (HSCs) and an increase in proliferation of lymphocytes in bone marrow, spleen and thymus as well as a significant suppression of cell apoptosis in these organs. The strongest alterations were found in the early disease phase (18–24 days after immunization) and were less pronounced in later EAE stages (40 days after EAE induction). We conclude that a significant increase in DNase and proteolytic activities of antibodies may be considered the earliest statistically significant marker of MOG‐induced EAE in mice. The possible differences in immune system reorganizations during preclinical phases of the disease, acute and late EAE, leading to production of different auto‐antibodies and abzymes as well other changes are discussed.

[1]  E. Granieri,et al.  Comparison of Antibodies Hydrolyzing Myelin Basic Protein from the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis , 2014, PloS one.

[2]  E. Granieri,et al.  Comparison of DNA-Hydrolyzing Antibodies from the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis , 2014, PloS one.

[3]  Bhanu P. Jena,et al.  Journal of Cellular and Molecular Medicine , 2014, Journal of Cellular and Molecular Medicine.

[4]  J. Goverman,et al.  Modeling the heterogeneity of multiple sclerosis in animals. , 2013, Trends in immunology.

[5]  G. Nevinsky Natural Catalytic Antibodies in Norm and in HIV-Infected Patients , 2011 .

[6]  F. Kasenga Understanding HIV/AIDS Management and Care - Pandemic Approaches in the 21st Century , 2011 .

[7]  V. Buneva,et al.  Natural Catalytic Antibodies in Norm, Autoimmune, Viral, and Bacterial Diseases , 2010, TheScientificWorldJournal.

[8]  V. Buneva,et al.  Nucleotide-hydrolyzing antibodies from the sera of autoimmune-prone MRL-lpr/lpr mice. , 2009, International immunology.

[9]  R. Beynon,et al.  Limited variation in the major urinary proteins of laboratory mice , 2009, Physiology & Behavior.

[10]  Daniel Thomas,et al.  Recognition and Degradation of Myelin Basic Protein Peptides by Serum Autoantibodies: Novel Biomarker for Multiple Sclerosis1 , 2008, The Journal of Immunology.

[11]  G. Nevinsky,et al.  Formation of different abzymes in autoimmune-prone MRL-lpr/lpr mice is associated with changes in colony formation of haematopoietic progenitors , 2007, Journal of cellular and molecular medicine.

[12]  V. Buneva,et al.  Antibodies with amylase activity from the sera of autoimmune‐prone MRL/MpJ‐lpr mice , 2006, FEBS letters.

[13]  O. Favorova,et al.  Metal-dependent hydrolysis of myelin basic protein by IgGs from the sera of patients with multiple sclerosis. , 2006, Immunology letters.

[14]  O. M. Durova,et al.  Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[15]  O. Favorova,et al.  Hydrolysis of myelin basic protein by IgM and IgA antibodies from the sera of patients with multiple sclerosis. , 2005, Medical science monitor : international medical journal of experimental and clinical research.

[16]  V. Buneva,et al.  Natural Catalytic Antibodies – Abzymes , 2005 .

[17]  A. Kulminskaya,et al.  Catalytic properties of IgMs with amylolytic activity isolated from patients with multiple sclerosis. , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[18]  O. Favorova,et al.  Hydrolysis of myelin basic protein by polyclonal catalytic IgGs from the sera of patients with multiple sclerosis , 2004, Journal of cellular and molecular medicine.

[19]  A. Kulminskaya,et al.  Human Abzymes with Amylolytic Activity , 2004 .

[20]  V. Buneva,et al.  Catalytic antibodies in healthy humans and patients with autoimmune and viral diseases , 2003, Journal of cellular and molecular medicine.

[21]  S. Muller,et al.  Anti-nucleosome antibodies and T-cell response in systemic lupus erythematosus. , 2002, Annales de medecine interne.

[22]  Y. Nishi Evolution of catalytic antibody repertoire in autoimmune mice. , 2002, Journal of immunological methods.

[23]  V. Buneva,et al.  Hematopoietic progenitor colony formation in the immunopathogenesis of the autoimmune disorder in MRL/MpJ-lpr mice. , 2002, Russian journal of immunology : RJI : official journal of Russian Society of Immunology.

[24]  H. Hartung,et al.  New concepts in the immunopathogenesis of multiple sclerosis , 2002, Nature Reviews Neuroscience.

[25]  O. Favorova,et al.  Catalytic heterogeneity of polyclonal DNA-hydrolyzing antibodies from the sera of patients with multiple sclerosis. , 2001, Immunology letters.

[26]  A. Bar-Or,et al.  The Neuroimmunology of Multiple Sclerosis: Possible Roles of T and B Lymphocytes in Immunopathogenesis , 2001, Journal of Clinical Immunology.

[27]  D. Burton,et al.  Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Cross,et al.  B cells and antibodies in CNS demyelinating disease , 2001, Journal of Neuroimmunology.

[29]  H. Hartung,et al.  Patients with active relapsing‐remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: Implications for remyelination , 2000, Annals of neurology.

[30]  H. Hartung,et al.  The role of B cells and autoantibodies in multiple sclerosis , 2000, Annals of neurology.

[31]  P. Schultz,et al.  Opportunities at the interface of chemistry and biology. , 1999, Trends in cell biology.

[32]  V. A. Naumov,et al.  Polyclonal antibodies from blood and cerebrospinal fluid of patients with multiple sclerosis effectively hydrolyze DNA and RNA. , 1998, Biochemistry. Biokhimiia.

[33]  I. Astsaturov,et al.  Novel functional activities of anti-dna autoantibodies from sera of patients with lymphoproliferative and autoimmune diseases , 1998, Applied biochemistry and biotechnology.

[34]  Dan S. Tawfik,et al.  Unexpectedly high occurrence of catalytic antibodies in MRL/lpr and SJL mice immunized with a transition-state analog: is there a linkage to autoimmunity? , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Avrameas,et al.  IgG auto- and polyreactivities of normal human sera. , 1993, Molecular immunology.

[36]  N. Copeland,et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.

[37]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[38]  Takato O. Yoshida,et al.  Organ-specific and systemic autoimmune diseases originate from defects in hematopoietic stem cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Y. Shoenfeld,et al.  Autoimmune diseases other than lupus share common anti-DNA idiotypes. , 1988, Immunology letters.

[40]  D. Caputo,et al.  Neuroimmunology in multiple sclerosis , 1983, The Italian Journal of Neurological Sciences.

[41]  V. Buneva,et al.  Autoantibodies and Natural Catalytic Antibodies in Health, Multiple Sclerosis, and Some Other Diseases , 2012 .

[42]  Kim D. Janda,et al.  Catalytic antibodies , 2007, Cell Biochemistry and Biophysics.

[43]  H. Sinohara,et al.  Does catalytic activity of bence-jones proteins contribute to the pathogenesis of multiple myeloma? , 2000, Applied biochemistry and biotechnology.

[44]  S. Nagata,et al.  Fas and Fas ligand: lpr and gld mutations. , 1995, Immunology today.

[45]  A. Coutinho,et al.  Natural autoantibodies. , 1995, Current opinion in immunology.

[46]  S. Benkovic,et al.  Recent developments in catalytic antibodies. , 1993, International reviews of immunology.

[47]  Richard A. Lerner,et al.  Antibodies as enzymes , 1987 .